Table 3.
Cost and clinical outcomes of 100,000 patients suspected with CDI from the two different diagnostic strategies.
| Test Outcome | Cost in JPY (USD) | Number of Deaths | Total Number of True Positive Patients Diagnosed | Cost per CDI Diagnosed in JPY (USD) | Incremental Cost per Death Avoided in JPY (USD) | |
|---|---|---|---|---|---|---|
| NAAT alone | Positive | 12,731,457,123 (136,662,271) |
3096 | 26,683 | 501,951 (5388) |
2,488,533 (26,712) |
| Negative | 662,189,183 (7,108,085) |
87 | ||||
| Sub Total | 13,393,646,307 (143,770,355) |
3183 | ||||
| GDH/toxin followed byNAAT | Positive | 11,610,628,467 (124,631,048) |
2893 | 24,934 | 528,097 (5669) |
- |
| Negative | 1,557,131,480 (16,714,593) |
380 | ||||
| Sub Total | 13,167,759,947 (141,345,641) |
3274 | ||||
| Difference | 225,886,360 (2,424,714) |
−91 | 1749 | −26,146 (−281) |
- |
CDI: Clostridioides difficile infection; GDH: glutamate dehydrogenase; NAAT: Nucleic Acid Amplification Test.